Clinical Trials

Phase Ib trial of pembrolizumab administered following adoptive cell therapy- A multiple cohort study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

 

Dr. Marcus Butler, Princess Margaret Cancer Centre
Approved April 23, 2018 | Project value $ 2,440,424 | 2 partners | $500,000 from BioCanRx

 

Eligible cancers: Melanoma and ovarian cancer
Keywords: pembrolizumab, adoptive cell therapy, combination therapy, tumor infiltrating lymphocytes (TIL), IL-2

 

 
 

 
 

Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143

 

Dr. Glenwood Goss, Ottawa Hospital Research Institute
Approved April 23, 2018 | Project value $18,041,777 | 4 partners | $779,777 from BioCanRx

 

Eligible cancers: Solid malignancies
Keywords: biomarkers, immune checkpoint inhibitor, Avelumab, Debio1143, combination therapy, SMAC mimetic

 

 
 

 
 

PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN IMMUNOTHERAPY BROADENING THE SCOPE OF APPLICATION FOR PRECISION THERAPEUTICS

 

Drs Roy and Perreault, Hôpital Maisonneuve-Rosemont, Université de Montréal
Approved July 6, 2017 | Project value $2,301,397 | 5 partners | $796,397 from BioCanRx

 

Eligible cancers: hematologic cancers (specifically lymphoid HCs)
Keywords: T cells, Minor Histocompability Antigens (MiHAs), hematologic cancers, Graph-Versus-Tumour-Effect (GVTE)

 

 
 

 
 

A PHASE 1/2, MULTICENTER, OPEN-LABEL TRIAL OF ONCOLYTIC MG1 EXPRESSING MUTANT HUMAN PAPILLOMA VIRUS (HPV) E6 AND E7 (MG1-E6E7), WITH ADENOVIRUS VACCINE EXPRESSING MUTANT HPV E6 AND E7 (AD-E6E7) IN PATIENTS WITH HPV POSITIVE SOLID TUMOURS

 

Drs Lichty, Ungerechts and Bell, McMaster University, The Ottawa Hospital Research Institute, University of Ottawa
Approved April 28, 2017 | Project value $6,002,065 | 1 partners | $780,665 from BioCanRx

 

Eligible cancers: human papilloma virus (specifically HPV-positive associated tumours)
Keywords: MG1, mutant human papilloma virus, E6, E7, MG1-E6E7, Adenovirus vaccine, Ad-E6E7, Ad/MG1-E6E7

 

 
 

 
 

CLINICAL TRIAL TO TEST THE ONCOLYTIC VACCINE APPROACH IN COMBINATION WITH CHECKPOINT INHIBITOR ANTIBODIES

 

Dr. Marcus Butler, Princess Margaret Cancer Centre, University Health Network
Approved June 10, 2015 | Project value $7.9 million | 3 partners | $750,000 from BioCanRx

 

Eligible cancers: anal, bladder, breast, cervical, colon, esophageal, kidney, liver, lung, melanoma, mouth, ovarian, pancreatic, prostate, stomach, uterine
Keywords: oncolytic virus, oncolytic vaccine, antibody, immune checkpoint inhibitor, anti-PD-1 antibody, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3

 

 
 

 
 

EVALUATING ADOPTIVE CELL THERAPY TO TREAT OVARIAN CANCER USING TILS CONDITIONED WITH DENDRITIC CELLS

 

Dr. Pamela Ohashi, Princess Margaret Cancer Centre, University Health Network
Approved June 10, 2015 | Project value $1.48 million | 1 partner | $592,000 from BioCanRx

 

Eligible cancers: ovarian
Keywords: adoptive cell therapy, TIL cells, tumour-infiltrating lymphocytes, dendritic cells

 

 
 

 
 

PHASE I STUDY OF THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML) USING AUTOLOGOUS AML CELLS ENGINEERED TO EXPRESS IL-12

 

Dr. Christopher Paige, University Health Network
Approved September 29, 2015 | Project value $1.3 million | 3 partners | $488,638 from BioCanRx

 

Eligible cancers: Acute Myeloid Leukemia (AML)
Keywords: adoptive cell therapy, IL-12, Interleukin 12, autologous leukemia cells, AML